BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20466203)

  • 1. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.
    Sadanaga T; Sadanaga M; Ogawa S
    J Am Coll Cardiol; 2010 May; 55(20):2225-31. PubMed ID: 20466203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-dimer level influences thromboembolic events in patients with atrial fibrillation.
    Nozawa T; Inoue H; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2006 Apr; 109(1):59-65. PubMed ID: 15992948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy.
    Vene N; Mavri A; Kosmelj K; Stegnar M
    Thromb Haemost; 2003 Dec; 90(6):1163-72. PubMed ID: 14652652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation.
    Sadanaga T; Kohsaka S; Mitamura H; Ogawa S
    Heart Vessels; 2011 Sep; 26(5):530-5. PubMed ID: 21188387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy.
    Sadanaga T; Kohsaka S; Ogawa S
    Cardiology; 2010; 117(1):31-6. PubMed ID: 20881392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.
    Christersson C; Wallentin L; Andersson U; Alexander JH; Ansell J; De Caterina R; Gersh BJ; Granger CB; Hanna M; Horowitz JD; Huber K; Husted S; Hylek EM; Lopes RD; Siegbahn A
    J Thromb Haemost; 2014 Sep; 12(9):1401-12. PubMed ID: 24942912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of left atrial coagulation activity among paroxysmal atrial fibrillation patients.
    Yashiro Y; Arimoto T; Hashimoto N; Tamura H; Iwayama T; Ishigaki D; Kumagai Y; Nishiyama S; Takahashi H; Shishido T; Miyamoto T; Watanabe T; Kubota I
    Circ J; 2015; 79(1):61-9. PubMed ID: 25391906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm.
    Lip GY; Rumley A; Dunn FG; Lowe GD
    Int J Cardiol; 1995 Oct; 51(3):245-51. PubMed ID: 8586473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation.
    Matsumoto M; Sakaguchi M; Okazaki S; Furukado S; Tagaya M; Etani H; Shimazu T; Yoshimine T; Mochizuki H; Kitagawa K
    Cerebrovasc Dis; 2013; 35(1):64-72. PubMed ID: 23428999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study.
    Genovesi S; Rebora P; Gallieni M; Stella A; Badiali F; Conte F; Pasquali S; Bertoli S; Ondei P; Bonforte G; Pozzi C; Rossi E; Valsecchi MG; Santoro A
    J Nephrol; 2017 Aug; 30(4):573-581. PubMed ID: 27834042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy.
    Mitusch R; Siemens HJ; Garbe M; Wagner T; Sheikhzadeh A; Diederich KW
    Thromb Haemost; 1996 Feb; 75(2):219-23. PubMed ID: 8815563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.
    Rivera-Caravaca JM; Roldán V; Romera M; Esteve-Pastor MA; Valdés M; Lip GYH; Vicente V; Marín F
    J Gen Intern Med; 2018 Jun; 33(6):847-854. PubMed ID: 29569024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
    Li-Saw-Hee FL; Blann AD; Lip GY
    Stroke; 2000 Apr; 31(4):828-33. PubMed ID: 10753983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
    Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentre F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
    Cerebrovasc Dis; 2001; 12(3):245-52. PubMed ID: 11641591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble fibrin monomer complex levels during oral anticoagulant therapy do not predict subsequent thromboembolic events in patients with permanent atrial fibrillation.
    Sadanaga T; Mitamura H
    Int J Cardiol; 2013 Sep; 168(1):578-80. PubMed ID: 23465239
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis.
    Wu N; Chen X; Cai T; Wu L; Xiang Y; Zhang M; Li Y; Song Z; Zhong L
    Can J Cardiol; 2015 Mar; 31(3):278-86. PubMed ID: 25746020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
    Yamamoto R; Nakae Y; Tanaka F; Johkura K
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
    Siegbahn A; Oldgren J; Andersson U; Ezekowitz MD; Reilly PA; Connolly SJ; Yusuf S; Wallentin L; Eikelboom JW
    Thromb Haemost; 2016 May; 115(5):921-30. PubMed ID: 26818781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.